Top Story

Bevacizumab improves pathological complete response in HER-2–negative early breast cancer

June 30, 2015

The addition of four cycles of bevacizumab to standard neoadjuvant chemotherapy significantly improved the pathological complete response rate among patients with HER-2–negative early-stage breast cancer, according to the results of a phase 3 study.

However, the impact of improved pathological complete response on OS and DFS remains undetermined, according to the researchers.

Steven A. Narod, MD, FRCPC In the Journals

PALB2 mutations may increase risk for breast cancer mortality

June 29, 2015
Women harboring a PALB2 mutation face an increased risk for breast cancer and a potentially increased risk for breast cancer mortality compared with non-carriers…
William J. Gradishar, MD, FACP Meeting News Coverage

Top Takeaways from ASCO: HER-2–positive breast cancer

June 23, 2015
CHICAGO — From 5 days of research presented at ASCO 2015, several trials investigating treatment specifically for HER-2–positive breast cancers stood out…
William J. Gradishar, MD, FACP Meeting News Coverage

Top Takeaways from ASCO: Breast Cancer

June 23, 2015
CHICAGO — Physicians managing patients with various breast cancer diagnoses left ASCO 2015 with new data to consider when making decisions every day – some…
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
Meeting News Coverage Video
VIDEO: Uptake of chemoprevention for breast cancer remains poor

VIDEO: Uptake of chemoprevention for breast cancer remains poor

June 9, 2015
CHICAGO Patricia Ganz, MD, medical oncologist at the Jonsson Comprehensive Cancer Center at UCLA, discusses an…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
In the Journals

Bevacizumab improves pathological complete response in HER-2–negative early breast cancer

June 30, 2015
The addition of four cycles of bevacizumab to standard neoadjuvant chemotherapy significantly improved the pathological complete response rate among…
Steven A. Narod, MD, FRCPC In the Journals

PALB2 mutations may increase risk for breast cancer mortality

June 29, 2015
Women harboring a PALB2 mutation face an increased risk for breast cancer and a potentially increased risk for breast cancer mortality compared with…
William J. Gradishar, MD, FACP Meeting News Coverage

Top Takeaways from ASCO: HER-2–positive breast cancer

June 23, 2015
CHICAGO — From 5 days of research presented at ASCO 2015, several trials investigating treatment specifically for HER-2–positive breast…
William J. Gradishar, MD, FACP Meeting News Coverage

Top Takeaways from ASCO: Breast Cancer

June 23, 2015
CHICAGO — Physicians managing patients with various breast cancer diagnoses left ASCO 2015 with new data to consider when making decisions…
In the Journals

Patients with luminal A breast cancer may not benefit from radiation therapy

June 18, 2015
Patients with low-risk luminal A breast cancer may not need radiation therapy following breast-conserving surgery due to their low risk for…
VIDEO: Margin shaving can reduce subsequent surgeries for women with breast cancer Meeting News CoverageVideo

VIDEO: Margin shaving can reduce subsequent surgeries for women with breast cancer

June 16, 2015
CHICAGO — Thomas J. Lynch, MD, director of Yale Cancer Center and a HemOnc Today Editorial Board member, discusses results of a randomized…
Karla Kerlikowske, MD In the Journals

Dense breasts alone may not justify additional screening for breast cancer

June 16, 2015
Dense breast tissue alone may not correspond with a higher risk for interval breast cancer and, thus, should not be considered the sole criterion for…
Meeting News Coverage

DCIS survival benefit from surgery varies by nuclear grade

June 12, 2015
CHICAGO — Surgical management of ductal carcinoma in situ improved survival outcomes compared with non-operative management among patients with…
Meeting News CoveragePerspective

Neratinib prolongs invasive DFS in HER-2–positive early-stage breast cancer

June 11, 2015
CHICAGO — Women with HER-2–positive early-stage breast cancer who received 12 months of neratinib after adjuvant chemotherapy and…
Kimberly L. Blackwell, MD Cover StoryPublication Exclusive

‘Educational curve’ required before biosimilars are fully embraced in cancer treatment armamentarium

HemOnc Today, June 10, 2015
When the Affordable Care Act established an abbreviated licensure pathway for biosimilars in the United States, development of the agents accelerated…
More Headlines »
morganatic-roan